IN8bio, Inc. Form 8-K Summary
Business Context and Reporting Period
IN8bio, Inc. filed a Form 8-K dated December 11, 2023, under Item 8.01 to report updated clinical data presented at the 65th American Society of Hematology Annual Meeting. The update concerns INB-100, an investigational therapy evaluated in a Phase 1 investigator-sponsored trial involving patients with hematologic malignancies undergoing haploidentical stem cell transplantation.
Key Clinical and Financial Information
- All 10 evaluable treated patients remained alive, progression free, and in durable complete remission as of November 3, 2023.
- Six patients were relapse free for more than one year, and all patients had passed 100 days post-treatment.
- Two patients had remained progression free for more than three years.
- Reported progression-free durations ranged from 4.9 months to 42.7 months.
- In-vivo expansion and persistence of allogeneic gamma-delta T cells were observed 365 days after a single INB-100 administration.
- At day 60, patients receiving dose level 2 had gamma-delta T-cell levels 48.9 times those of patients undergoing HSCT without INB-100 and 7.6 times those of dose-level 1 patients.
- At day 365, dose-level 2 patients had average gamma-delta T-cell levels 2.7 times those of dose-level 1 patients.
- Early post-infusion increases in pro-inflammatory cytokines indicated broad immune activation. Elevated CD4+ and CD8+ T cells, natural killer cells, and B cells were also observed.
- Low-grade acute graft-versus-host disease occurred in 60% of patients; no dose-limiting toxicities were observed.
- The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes, Outlook, Risks, and Unusual Items
The filing reports updated clinical observations rather than financial results or a change in formal guidance. The data suggest durable remission, immune-cell persistence, dose-related expansion, and a tolerable safety profile in this small Phase 1 population. However, the results are preliminary, involve only 10 evaluable treated patients, and come from an investigator-sponsored trial. The reported 60% incidence of low-grade acute graft-versus-host disease remains a relevant safety consideration. The filing provides no commercialization forecast, regulatory approval timeline, financing outlook, or additional risk disclosures.
Important Facts for Investors to Verify
- Whether the reported remission and progression-free outcomes persist with longer follow-up and in larger, controlled studies.
- The definition of the HSCT-only comparison group used for the reported 48.9-times and 7.6-times cell-level comparisons.
- Detailed patient characteristics, evaluability criteria, follow-up duration, and statistical methodology.
- The full safety profile, including the nature and duration of graft-versus-host disease and any later-emerging toxicities.
- Future clinical development plans, regulatory interactions, funding needs, and the company’s financial position, none of which are provided in this filing.